123I-Ioflupane SPECT and 18F-FDG PET Combined Use in the Characterization of Movement and Cognitive Associated Disorders in Neurodegenerative Diseases.

Current Alzheimer Research
Susanna NuvoliGiuseppe Madeddu

Abstract

Both movement (MD) and cognitive (CD) disorders can occur associated in some neurodegenerative diseases, such as Parkinson's disease (PD) and Alzheimer's disease (AD). We further investigated the usefulness of 123I-Ioflupane SPECT and 18F-FDG PET combined use in patients with these disorders in the early stage. We retrospectively enrolled twenty-five consecutive patients with MD and CD clinical symptoms of recent appearance. All patients had undergone neurologic examination, neuropsychological tests, and magnetic resonance imaging. 123I-Ioflupane SPECT was performed in all cases, followed by 18F-FDG PET two weeks later. In the two procedures, both qualitative (QL) and quantitative (QN) image analyses were determined. In patients with both 123I-Ioflupane SPECT and 18F-FDG PET pathologic data, associated dopaminergic and cognitive impairments were confirmed in 56% of cases. Pathologic SPECT with normal PET in 16% of cases could diagnose MD and exclude an associated CD, despite clinical symptoms. On the contrary, normal SPECT with pathologic PET in 28% of cases could exclude basal ganglia damage while confirming CD. QN 123I-Ioflupane SPECT analysis showed better performance than QL since QN correctly characterized two cases of MD ...Continue Reading

References

Dec 5, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·W PirkerT Brücke
Apr 17, 2002·Journal of Neural Transmission·K A JellingerW Poewe
May 7, 2005·Neuropathology : Official Journal of the Japanese Society of Neuropathology·Richard A ArmstrongNigel J Cairns
Jun 16, 2005·NeuroImage·Thomas EckertD Eidelberg
Dec 20, 2005·Lancet Neurology·Eduardo TolosaWerner Poewe
Sep 18, 2009·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Seok Ming LimChristopher C Rowe
Oct 20, 2009·European Journal of Nuclear Medicine and Molecular Imaging·Jacques DarcourtKoen Van Laere
Oct 20, 2009·European Journal of Nuclear Medicine and Molecular Imaging·Andrea VarroneUNKNOWN European Association of Nuclear Medicine Neuroimaging Committee
Jan 20, 2010·Lancet Neurology·Clifford R JackJohn Q Trojanowski
Jan 29, 2010·Movement Disorders : Official Journal of the Movement Disorder Society·David R Williams, Andrew J Lees
Jun 23, 2010·European Journal of Nuclear Medicine and Molecular Imaging·Barbara PalumboGiuseppe Madeddu
Jun 11, 2011·Movement Disorders : Official Journal of the Movement Disorder Society·Irene LitvanDaniel Weintraub
Aug 4, 2011·Brain : a Journal of Neurology·Jeffrey L CummingsPaul Kemp
Sep 8, 2011·Progress in Neurobiology·David J Brooks, Nicola Pavese
Jan 3, 2013·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·A BerardelliM Vidailhet
May 13, 2014·Parkinsonism & Related Disorders·Juho JoutsaValtteri Kaasinen
Jul 19, 2014·Journal of Nuclear Medicine Technology·Prashant JolepalemDafang Wu
Oct 10, 2014·Neurology·Danna JenningsUNKNOWN PARS Investigators
Aug 1, 2015·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Sabine HellwigPhilipp T Meyer
Oct 21, 2015·Journal of Parkinson's Disease·Philipp MahlknechtWerner Poewe
Feb 16, 2016·Ageing Research Reviews·Takashi KatoKengo Ito
Jun 22, 2016·Journal of Neural Transmission·Elina MäkinenValtteri Kaasinen
Aug 3, 2016·Clinical Medicine : Journal of the Royal College of Physicians of London·Gennaro PaganoMarios Politis
Sep 16, 2016·Journal of Molecular Neuroscience : MN·Xuling LiPeng Lei
Oct 25, 2016·Current Alzheimer Research·Susanna NuvoliGiuseppe Madeddu
Nov 5, 2016·Expert Review of Neurotherapeutics·Stuart H IsaacsonJohn Seibyl
Sep 16, 2017·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Philipp T MeyerSabine Hellwig
Oct 11, 2017·Handbook of Clinical Neurology·Gabor G Kovacs
Mar 8, 2018·Methods in Molecular Biology·Filippo BaldacciUNKNOWN Alzheimer Precision Medicine Initiative (APMI)
May 21, 2018·European Journal of Nuclear Medicine and Molecular Imaging·Zuzana WalkerUNKNOWN EANM-EAN Task Force for the recommendation of FDG PET for Dementing Neurodegenerative Disorders
Jul 27, 2018·American Journal of Alzheimer's Disease and Other Dementias·Auda Fares, Dieter Borrmann
Aug 29, 2018·Clinical Nuclear Medicine·Sahar MirpourRathan M Subramaniam
Mar 9, 2019·Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging·Jing TangArman Rahmim
Mar 23, 2019·Annals of Nuclear Medicine·Gemma RobertsAlan J Thomas
Jul 17, 2019·Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging·Susanna NuvoliBarbara Palumbo
Nov 28, 2019·Deutsches Ärzteblatt International·Ralph BuchertJürgen Gallinat
Jan 14, 2020·Journal of Alzheimer's Disease : JAD·Viviana FrantellizziGiuseppe De Vincentis
May 2, 2020·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Sumit DasLee Cyn Ang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Forebrain- Circuits

Basal forebrain is a region in the brain important for production of acetylcholine and is the major cholinergic output of the CNS. Discover the latest research on circuits in the basal forebrain here.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.

Basal ganglia in Parkinson's disease (MDS)

The basal ganglia is comprised of the neostriatum, the external and internal pallidal segments, the subthalamic nucleus, the substantia nigra pars reticulata, and the pars compacta of the substantia nigra. The basal ganglia circuitry is responsible for the correct execution of voluntary movements and is implicated in Parkinson's disease. Here is the latest research investigating the basal ganglia in Parkinson's disease.